Mülder DT, Hahn AI, Huang RJ, Zhou MJ, Blake B, Omofuma O, Murphy JD, Gutiérrez-Torres DS, Zauber AG, O’Mahony JF, Constanza Camargo MC, Ladabaum U, Yeh JM, Hur C, Lansdorp-Vogelaar I, Meester R and Laszkowska M. Prevalence of Gastric Precursor Lesions in Countries with Differential Gastric Cancer Burden: A Systematic Review & Meta-Analysis; Clinical Gastroenterology and Hepatology, 2024. https://doi.org/10.1016/j.cgh.2024.02.023.
Sun D, Mülder DT, Li Y, Nieboer D, Park JY, Suh M, Hamashima C, Han W, O’Mahony JF and Lansdorp-Vogelaar IThe Effect of Nationwide Organized Cancer Screening Programs on Gastric Cancer Mortality: A Synthetic Control Study; Gastroenterology, 2024. https://doi.org/10.1053/j.gastro.2023.11.286.
Paulden M, Sampson C, O'Mahony JF, Spackman E, McCabe C, Round F, and Snowsill T. Logical Inconsistencies in the Health Years in Total and Equal Value of Life-Years Gained; Value in Health, 2023. https://doi.org/10.1016/j.jval.2023.11.009.
Charlton V, DiStefano M, Mitchell P, Morrell L, Rand L, Badano G, Baker R, Calnan M, Chalkidou K, Culyer A, Howdon D, Hughes D, Lomas J, Max C, McCabe C, O’Mahony JF, Paulden M, Pemberton-Whiteley Z, Rid A, Scuffham P, Sculpher M, Shah K, Weale A and Wester G. We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment; Health Economics, Policy and Law, 2023. https://doi.org/10.1017/S1744133123000038.
Mülder DT, van den Puttelaar R, Meester RGS, O'Mahony JF and Lansdorp-Vogelaar I. Development and validation of colorectal cancer risk prediction tools: a comparison of models; International Journal of Medical Informatics, 2023. https://doi.org/10.1016/j.ijmedinf.2023.105194.
Scheffer MMJ, Coffeng L, and O'Mahony JF. Appropriateness of strategy comparisons in cost-effectiveness analyses of infant pneumococcal vaccination; a systematic review; International Journal of Technology Assessment in Health Care, 2023. https://doi.org/10.1017/S0266462323000351.
Pokharel R, Lin YS, McFerran E & O’Mahony JF. A Systematic Review of Cost-Effectiveness Analyses of Colorectal Cancer Screening in Europe: Have Studies Included Optimal Screening Intensities?; Applied Health Economics and Health Policy, 2023. https://doi.org/10.1007/s40258-023-00819-3.
Lin Y, O'Mahony JF, and van Rosmalen. A Simple Cost-Effectiveness Model of Screening: An Open-Source Teaching and Research Tool Coded in R; PharmacoEconomics - Open, 2023. https://doi.org/10.1007/s41669-023-00414-1.
Kinchin I, Walshe V, Normand C, Coast J, Elliott R, Kroll T, Kinghorn P, Thompson A, Viney R, Currow D and O’Mahony JF; Expanding health technology assessment towards broader value: Ireland as a case study; International Journal of Technology Assessment in Health Care, vol. 39, Cambridge University Press, no. 1, p. e26. https://doi.org/10.1017/S0266462323000235.
Vancoppenolle JM, Koole SN, O'Mahony JF, Franzen N, Burgers JA, Retèl VP, and van Harten VH. Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe; Drug Discovery Today, 2023. https://doi.org/10.1016/j.drudis.2023.103620.
Burger EA, de Kok IMCM, O'Mahony JF, Rebolj M, Jansen EEL, de Bondt DD, Killen J, Hanley SJ, Castanon A, Regan MC, Kim JJ, Canfell K, and Smith MA. A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions; eLife, 2022, 11:e81711. DOI:/10.7554/eLife.81711
Fabbro M, Hahn K, Novaes O, Ó’Grálaigh M and O'Mahony JF, Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography; A Systematic Review Assessing Strategy Comparison and Risk Stratification; PharmacoEconomics - Open, 2022, DOI:/10.1007/s41669-022-00346-2.
Larkin J, Moriarty F, McGuinness S, Finucane K, Fitzgerald K, Smith SM, and O'Mahony JF, Variation of prescription drug prices in community pharmacies: A national cross-sectional study; Research in Social and Administrative Pharmacy, 2022, DOI:/10.1016/j.sapharm.2022.05.007.
McFerran E, O’Mahony JF, Naber S, Sharp L, Zauber AG, Lansdorp-Vogelaar I, and Kee F, Colorectal Cancer Screening within Colonoscopy Capacity Constraints; Can FIT-Based Programs Save More Lives by Trading off More Sensitive Test Cutoffs against Longer Screening Intervals? Medical Decision Making Policy & Practice, 2022, DOI:/10.1177/23814683221097064.
O’Mahony JF, Risk Stratification in Cost-Effectiveness Analyses of Cancer Screening; Intervention Eligibility, Strategy Choice, and Optimality; Medical Decision Making, 2021, DOI:/10.1177/0272989X211050918.
Almajed S, Alotaibi N, Zulfqar S, Dhuhaibawi Z, O’Rourke N, Gaule R, Byrne C, Barry AM, Keeley D, and O’Mahony JF, Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability; The European Journal of Health Economics, 2021, DOI:/10.1007/s10198-021-01365-2.
O’Mahony JF, Revision of Ireland’s Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs; PharmacoEconomics Open, 2021, DOI:/10.1007/s41669-021-00289-0.
Castanon A, Rebolj M, Burger EA, de Kok IMCM, Smith MA, Hanley SJB, Carozzi FM, Peacock S, and O'Mahony JF, Cervical screening during the COVID-19 pandemic: optimising recovery strategies. The Lancet Public Health, 2021, DOI: /10.1016/S2468-2667(21)00078-5.
O’Mahony JF, Paulden M, and McCabe MC, NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests. PharmacoEconomics, 2021, DOI: /10.1007/s40273-020-00990-8.
O’Mahony JF, Interpreting cost-effectiveness ratios in a cost-effectiveness analysis of risk-tailored prostate screening: A critique of Callender et al. HRB Open Research, 2020, DOI: 10.12688/hrbopenres.13043.1.
O’Mahony JF, Does Cost‑Effectiveness Analysis Really Need to Abandon the Incremental Cost‑Effectiveness Ratio to Embrace Net Benefit? PharmacoEconomics, 2020, DOI: 10.1007/s40273-020-00931-5.
Kwok MQT, Kareem MA, Cash MJ, Laferty F, Tobin K, and O’Mahony JF, Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses. PharmacoEconomics, 2020, DOI: 10.1007/s40273-020-00916-4.
O’Mahony JF and Paulden M, The Joint Committee on Vaccination and Immunisation’s Advice on Extending Human Papillomavirus Vaccination to Boys: Were Cost-Effectiveness Analysis Guidelines Bent to Achieve a Politically Acceptable Decision? Value in Health, 2019, 22(11), DOI: 10.1016/j.jval.2019.07.010.
O’Mahony JF and Paulden M, Appraising the cost-effectiveness of vaccines in the UK: Insights from the Department of Health Consultation on the revision of methods guidelines. Vaccine, 2019, 37(21), DOI: 10.1016/j.vaccine.2019.03.072.
O’Mahony JF, Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes? PharmacoEconomics, 2019, 37, 627-630, DOI: 10.1007/s40273-019-00781-w.
Mone F, O’Mahony JF, Tyrrell E, Mulcahy C, McParland P, Breathnach F, Morrison JJ, Higgins J, Daly S, Cotter A, Hunter A, Dicker P, Tully E, Malone FD, Normand C, and McAuliffe FM, Preeclampsia Prevention Using Routine Versus Screening Test–Indicated Aspirin in Low-Risk Women: A Cost-Effectiveness Analysis, Hypertension, 2018, 72: 1391-1396, DOI: 10.1161/HYPERTENSIONAHA.118.11718.
Chen TC, Wanniarachige D, Murphy S, Lockhart K and O'Mahony J, Surveying the Cost Effectiveness of the 20 Procedures with the Largest Public Health Services Waiting Lists in Ireland: Implications for Ireland’s Cost-Effectiveness Threshold, Value in Health, 2018, 21(8), DOI: 10.1016/j.jval.2018.02.013.
Hernon MJ, Hall AM, O'Mahony JF, Normand C and Hurley DA, Systematic Review of Costs and Effects of Self- Management Interventions for Chronic Musculoskeletal Pain: Spotlight on Analytic Perspective and Outcomes Assessment, Physical Therapy, 2017, 91(10) DOI: 10.1093/ptj/pzx073.
Ó Céilleachair A, O’Mahony JF, O’Connor M, O’Leary J, Normand C, Martin C and Sharp L, Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease :A systematic review, Quality of Life Research, 2017, 26(11), DOI: 10.1007/s11136-017-1628-z.
McFerran E, O'Mahony JF, Fallis R, McVicar D, Zauber AG and Kee F, Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy, Epidemiologic Reviews, 2017, 39(1), DOI: 10.1093/epirev/mxx002.
Paulden M, O’Mahony JF, McCabe C, Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine, PharmacoEconomics, 2017, 35(1), DOI 10.1007/s40273-016-0482-0.
Ekwunife OI, O’Mahony JF, Gerber Grote A, Mosch C, Paeck T, and Lhachimi SK, Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations, PharmacoEconomics, 2017, 35(1) DOI: 10.1007/s40273-016-0451-7.
Paulden M, O’Mahony JF and McCabe C, Determinants of Change in the Cost-Effectiveness Threshold, Journal of Medical Decision Making, 2017, 37(2), DOI: 10.1177/0272989X16662242.
O’Mahony JF and Coughlan D, The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System? PharmacoEconomics, 2016, 34(1), p5-11, DOI: 10.1007/s40273-015-0336-1.
O’Mahony JF and Normand C, HIQA’s CEA of Breast Screening: Pragmatic Policy Recommendations are Welcome, but ACERs Reported as ICERs are Not, Value in Health, 2015, 18(8), p941–45, DOI: 10.1016/j.jval.2015.08.009.
O’Mahony JF, Naber SK, Normand C, Sharp L, O’Leary JJ and de Kok IMCM. Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening, Value in Health, 2015, 18(8), p1138–51, DOI: 10.1016/j.jval.2015.09.2939.
O’Mahony JF, Newall AT, and van Rosmalen J, Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice, PharmacoEconomics, 2015, 33(12), p1255-68, DOI: 10.1007/s40273-015-0309-4.
Ekwunife O, Gerber-Grote A, Mosch C, O’Mahony JF, and Lhachimi S, Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review, Systematic Reviews, 2015, 4(68), p1-9, DOI: 10.1186/s13643-015-0057-8.
O’Mahony JF, van Rosmalen J, Mushkudiani NA, Goudsmit F-W, Eijkemans MJ, Heijnsdijk EA, Steyerberg E & Habbema JDF, The Influence of Disease Risk on the Optimal Time Interval between Screens for the Early Detection of Cancer A Mathematical Approach, Medical Decision Making, 32(2), 2014, p183-95, DOI: 10.1177/0272989X14528380.
Paulden M, O'Mahony JF, Culyer AJ, & McCabe C. Some Inconsistencies in NICE’s Consideration of Social Values, PharmacoEconomics, 32(11), 2014, p1043-53, DOI: 10.1007/s40273-014-0204-4.
O’Mahony JF, & Paulden M, NICE’s Selective Application of Differential Discounting: Ambiguous, Inconsistent, and Unjustified, Value in Health, 17(5), 2014, p493-6, DOI: 10.1016/j.jval.2013.02.014.
van Rosmalen J, Toy M, & O’Mahony JF, A Mathematical Approach for Evaluating Markov Models in Continuous Time without Discrete-Event Simulation, Medical Decision Making, 33(6), 2013, p767-79, DOI: 10.1177/0272989X13487947.
O’Mahony JF, van Rosmalen J, Zauber AG and van Ballegooijen M, Multicohort Models in Cost-Effectiveness Analysis Why Aggregating Estimates over Multiple Cohorts Can Hide Useful Information, Medical Decision Making, 33(3), 2013, p407-14, DOI: 10.1177/0272989X12453503.
O'Mahony JF, de Kok IMCM, van Rosmalen J, Habbema JDF, Brouwer WBF and van Ballegooijen M, Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts, Value in Health, 14(4), 2011, p438-42, DOI: 10.1016/j.jval.2010.09.009.